- Home
- GLV vs CTMX Comparison
GLV vs CTMX Comparison
Compare GLV & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLV
- CTMX
- Stock Information
- Founded
- GLV 2004
- CTMX 2008
- Country
- GLV United States
- CTMX United States
- Employees
- GLV N/A
- CTMX N/A
- Industry
- GLV Finance/Investors Services
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- GLV Finance
- CTMX Health Care
- Exchange
- GLV Nasdaq
- CTMX Nasdaq
- Market Cap
- GLV 72.1M
- CTMX 62.3M
- IPO Year
- GLV N/A
- CTMX 2015
- Fundamental
- Price
- GLV $5.52
- CTMX $0.78
- Analyst Decision
- GLV
- CTMX Buy
- Analyst Count
- GLV 0
- CTMX 6
- Target Price
- GLV N/A
- CTMX $5.77
- AVG Volume (30 Days)
- GLV 54.2K
- CTMX 688.7K
- Earning Date
- GLV 01-01-0001
- CTMX 03-10-2025
- Dividend Yield
- GLV 12.44%
- CTMX N/A
- EPS Growth
- GLV N/A
- CTMX N/A
- EPS
- GLV N/A
- CTMX 0.16
- Revenue
- GLV N/A
- CTMX $126,617,000.00
- Revenue This Year
- GLV N/A
- CTMX $22.55
- Revenue Next Year
- GLV N/A
- CTMX N/A
- P/E Ratio
- GLV N/A
- CTMX $4.83
- Revenue Growth
- GLV N/A
- CTMX 33.66
- 52 Week Low
- GLV $4.70
- CTMX $0.75
- 52 Week High
- GLV $6.06
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- GLV 49.97
- CTMX 40.63
- Support Level
- GLV $5.51
- CTMX $0.77
- Resistance Level
- GLV $5.60
- CTMX $0.83
- Average True Range (ATR)
- GLV 0.06
- CTMX 0.06
- MACD
- GLV 0.00
- CTMX 0.00
- Stochastic Oscillator
- GLV 65.62
- CTMX 13.04
About GLV Clough Global Dividend and Income Fund of beneficial interest
Clough Global Dividend and Income Fund is a closed-ended investment management company. The fund's investment objective is to provide a high level of total return. It invests in equity and debt securities in both U.S. and non-U.S. markets of companies of any market capitalization.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.